MarketLens
Sign Up

What Do the Latest SUMMIT Trial Data Mean for Bezuclastinib

7 months ago
SHARE THIS ON:

What Do the Latest SUMMIT Trial Data Mean for Bezuclastinib

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•3 weeks ago

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences said the FDA accepted its NDA for bezuclastinib in advanced systemic mastocytosis, based on positive APEX pivotal trial results showing clinically meaningful responses and disease m...
Stock News•2 months ago

Beat AML® Study Provides New Data on 14-Day vs. 28-Day Venetoclax-Azacitidine Treatment in AML

Beat AML study data published in Blood compares 14-day vs 28-day venetoclax-azacitidine dosing in older AML patients, potentially informing shorter treatment regimens.
Stock News•2 months ago

Curis Doses First Five Patients in TakeAim CLL Study

Curis dosed first five patients in TakeAim CLL study for emavusertib, an oral IRAK4/FLT3 inhibitor in chronic lymphocytic leukemia.

Breaking News

View All →

Top Headlines

View More →
Stock News•2 hours ago

Amazon plans $7 billion acquisition of Decart, a fast-growing AI startup

Stock News•3 hours ago

Amazon in Talks to Buy AI Startup Decart for Around $7 Billion

Stock News•4 hours ago

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOG

Stock News•6 hours ago

Amazon and Alphabet Just Committed $420 Billion to Data Centers. 1 Stock Is the Better Buy.

Stock News•6 hours ago

3 Quantum Computing Stocks Poised to Outperform IonQ and Rigetti This Month